The updated analysis of the IBIS-II trial showed that breast cancer incidence among postmenopausal women who are at high risk of developing the disease continued to be significantly reduced 5.9 years after stopping a 5-year treatment period with the aromatase inhibitor (AI) anastrozole. These results indicate a long-term preventive benefit with anastrozole for oestrogen receptor (ER)-positive breast cancer in postmenopausal women.
IBIS-II Prevention was designed to investigate whether 5 years of anastrozole can safely and effectively prevent breast cancer in postmenopausal women who are at high risk for developing the disease . This was the case if these women fulfilled any one of a number of criteria, such as having 2 or more blood relatives with breast cancer, having a mother or sister who developed breast cancer at an age <50, or having a mother or sister who had breast cancer in both breasts. The primary objective of this study was to determine t...
Please login to read the full text of the article.
If you have no account yet, please register now.
« S-1 shows promising results in combination with endocrine therapy Next Article
No higher pathologic complete response with atezolizumab added to chemotherapy »